CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia
Joshua Gustine(Boston University), Jorge J. Castillo(Dana-Farber Cancer Institute), Christopher J. Patterson(Dana-Farber Cancer Institute), Amanda Kofides(Shaanxi Research Association for Women and Family), Gloria Chan(Shaanxi Research Association for Women and Family), Maria Demos(Shaanxi Research Association for Women and Family), Nicholas Tsakmaklis(Shaanxi Research Association for Women and Family), Maria Luisa Guerrera(Harvard University), Andrew Keezer(Dana-Farber Cancer Institute), Manit Munshi(Dana-Farber Cancer Institute), Kirsten Meid(Shaanxi Research Association for Women and Family), Steven P. Treon(Dana-Farber Cancer Institute), Jiaji G. Chen(Shaanxi Research Association for Women and Family), Toni Dubeau(Shaanxi Research Association for Women and Family), Guang Yang(Blueprint Medicines (United States)), Xia Liu(National Clinical Research), Lian Xu(Huazhong Agricultural University), Zachary R. Hunter(Harvard University)
Cited by 39
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Immunopathology of Hyperinflammation in COVID-19
|American Journal Of Pathology|2020|526
Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders
|Clinical Infectious Diseases|2006|270
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
|Journal of Clinical Oncology|2018|176